Board of Directors
Brenton K. Ahrens (Chairman)
General Partner at Canaan Partners
Brent Ahrens joined Canaan in 1999 as a member of the Kauffman Fellows Program and is a part of the healthcare investment team at the firm. He has led investments in companies including DexCom (DXCM), Revivant (acquired by ZOLL), Peninsula Pharmaceuticals (acquired by JNJ), Cerexa (acquired by FRX), Calixa (acquired by CBST), Durata Therapeutics (DRTX, acquired by AGN), Elevation Pharmaceuticals (acquired by DNPUF); AtheroMed (acquired by VOLC); and Spinifex (acquired by NVS).
Mr. Ahrens serves on the boards of a number of private companies including Abyrx, a developer of biomaterials for use in surgery; EndoGastric Solutions, the leading medical device company with treatments for reflux disease; Relievant MedSystems, a maker of minimally invasive devices to relieve chronic back pain; Grey Wolf Therapeutics, a biotechnology company focused on immuno-oncology; Axcelius Holding Company, a drug discovery company focused on innate immune checkpoints in cancer; Transposon Therapeutics, a biopharmaceutical company focused on novel mechanisms to treat neurodegenerative diseases; OncoLinea Therapeutics, a biopharmaceutical company focused on novel mechanisms to treat cancers; and ThirtyFiveBio, a drug discovery company focused on the treatment of digestive system cancers.
Prior to joining Canaan, Mr. Ahrens worked in both commercial and technical roles at General Surgical Innovations, Ethicon (J&J), and IAP Research. He also has several surgical instrument patents to his credit and is a Registered Professional Engineer.
Mr. Ahrens earned an MBA from the Tuck School of Business at Dartmouth College after graduating with a B.S. and M.S. in Mechanical Engineering from the University of Dayton.
Managing Director, Arix Bioscience
Mark Chin has over ten years of experience in the life sciences industry. He is currently a managing director at Arix Bioscience and a director of Harpoon Therapeutics, Imara, Pyxis Oncology and a number of privately held biotechnology companies. Prior to Arix, Mark was a principal at Longitude Capital, where he focused on investments in both private and public biotechnology and medical technology companies. Prior to Longitude, he was a consultant at the Boston Consulting Group, where he was responsible for strategy and corporate development projects for pharmaceutical and biotechnology companies. Before BCG, Mark worked in corporate development at Gilead Sciences and market planning at Genentech.
Mark has an MBA from The Wharton School at the University of Pennsylvania, an MS in Biotechnology from the University of Pennsylvania, and a BS in Management Science from the University of California at San Diego.
Michael Dunne, MD
Chief Medical Officer at the Bill and Melinda Gates Medical Research Institute
Dr. Dunne currently serves as the chief medical officer at the Gates Medical Research Institute. Previously, Dr. Dunne served as the chief scientific officer of Iterum Therapeutics. Before Iterum, Dr. Dunne was the Chief Medical Officer of Durata Therapeutics, Inc. from 2009 until its acquisition by Actavis plc in 2014 and remained in a leadership role as part of the Actavis integration efforts to ensure successful transition of all priority development activities until 2015. From 1992 to 2009, Dr. Dunne served in a variety of roles in connection with the clinical development of numerous infectious disease compounds at Pfizer Inc., including as the Vice President, Therapeutic Head of Development for Infectious Disease from 2001 to 2009. Dr. Dunne also served as a member of the board of directors of Aviragen Therapeutics, Inc, a biotechnology company from 2015 to 2018. Dr. Dunne holds a BA in Economics from Northwestern University and an MD from the State University of New York Health Sciences Center. He completed his internal medicine residency and fellowships in infectious diseases and pulmonary medicine at Yale University School of Medicine.
Corey N. Fishman
CEO at Iterum Therapeutics plc
Corey Fishman has served as Chief Executive Officer since late 2015 when the company was formed. From 2010 to 2015, Mr. Fishman served as Chief Financial and Chief Operating Officer of Durata Therapeutics, Inc. overseeing all aspects of finance and administration, manufacturing, business development, strategy, international operations and portfolio optimization. While at Durata, he raised substantial capital, including a successful IPO and secondary public offering. Mr. Fishman also led the negotiation and sale of the company to Actavis plc.
Prior to Durata, Mr. Fishman served as Chief Financial Officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus company from 2008 to 2010. From 2002 to 2008, Mr. Fishman served in a leadership role at MedPointe Healthcare, Inc., a private equity backed specialty pharmaceutical company and became the Chief Financial Officer in 2006. Mr. Fishman had responsibility for finance and administration, portfolio optimization, manufacturing, strategy and business development. He led the development and implementation of a new strategic plan, which involved raising capital, restructuring debt, accelerating the growth of existing commercial assets and developing multiple line extensions to enhance future value, culminating in the successful sale of the company to Meda AB. From 1994 to 2002, Mr. Fishman held roles of increasing responsibility in both mid-size and large pharma.
Mr. Fishman was previously on the boards of Momenta Pharmaceuticals (Nasdaq: MNTA, acquired by Johnson & Johnson) and BioSpecifics Technology Corporation (Nasdaq: BSTC, acquired by Endo International plc).
Mr. Fishman holds a BA in Economics from the University of Illinois at Urbana-Champaign and an MSM in Finance from the Krannert School of Management at Purdue University.
Beth P. Hecht
Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings Inc.
Ms. Hecht has over 25 years of experience as a corporate executive in the life science industry and currently serves as Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), a speciality pharmaceutical company. From January 2019 to October 2021, Ms. Hecht served as senior vice president, general counsel and corporate secretary of Xeris Pharmaceuticals, Inc. Before Xeris, Ms. Hecht served as Managing Director and Chief Legal and Administrative Officer for Auven Therapeutics, a global biotechnology and pharmaceutical private equity firm. Ms. Hecht was previously a member of the Board of Directors of Neos Therapeutics (Nasdaq: NEOS) where she chaired the Nominating and Governance Committee and also served on the Board of Directors of Aytu BioScience Inc. (Nasdaq: AYTU) following its acquisition of Neos Therapeutics. Ms. Hecht is a graduate of Amherst College and Harvard Law School and started her career as an attorney specializing in intellectual property and corporate transactions at Willkie Farr & Gallagher (NY) and then Kirkland & Ellis (NY). She has established and led legal, compliance, licensing, human resources, and security departments at companies including Durata Therapeutics, Sun Products, MedPointe Inc. (formerly known as Carter-Wallace Inc.), Warner Chilcott PLC, ChiRex Ltd., and Alpharma Inc.
Ronald M. Hunt
Managing Director at New Leaf Venture Partners
Ron Hunt is a Managing Director at New Leaf Venture Partners, and focuses on investments in biopharmaceutical companies. Mr. Hunt was one of the founders of New Leaf following the spin out from the Sprout Group in 2005, and today has nearly 2 decades of venture capital investment experience. Mr. Hunt has played a significant role in many of the firm’s investments in biopharmaceuticals and in other sectors. Mr. Hunt is currently on the boards of Rallybio Holdings LLC and Harpoon Therapeutics Inc., and serves as director on the boards of a number of private companies. Mr. Hunt was previously on the boards of Neuronetics, Inc. (Nasdaq: STIM), Durata Therapeutics (Nasdaq: DRTX, acquired by Actavis), Relypsa (Nasdaq: RLYP), Cerexa (acquired by Forest Laboratories), Stromedix, Inc. (acquired by Biogen Idec), Aspreva Pharmaceuticals (Nasdaq: ASPV, acquired by Galenica, Inc.), Phase Forward (Nasdaq: PFWD, acquired by Oracle), and Pathology Partners (acquired by Caris Group).
Prior to joining Sprout in early 1998, Mr. Hunt was a consultant with the pharmaceutical industry practice at Coopers & Lybrand Consulting and then with The Health Care Group (a division of the Interpublic Group of companies). His consulting work spanned 4 years and focused on strategic and operational engagements for clients in the pharmaceutical and medical device industries. Prior to entering the consulting field, Mr. Hunt held a number of sales and marketing positions for a combined eight years with Johnson & Johnson and SmithKline Beecham Pharmaceuticals.
Mr. Hunt is a graduate of The Wharton School (MBA) and Cornell University (BS).
David G. Kelly
Executive Vice President at Horizon Therapeutics plc
David Kelly is a member of the Executive Committee of Horizon Therapeutics plc, a biopharmaceutical company listed on Nasdaq and headquartered in Dublin, Ireland, and a Director of its Irish operating subsidiary. He was formerly the Executive Vice President, Managing Director, Ireland and Company Secretary of Horizon. Prior to joining Horizon, Mr. Kelly served as Chief Financial Officer for Vidara Therapeutics, and was previously Chief Financial Officer of AGI Therapeutics. He also served as Senior Vice President of Warner Chilcott, a fully integrated specialty pharmaceutical company. While at Warner Chilcott, he led the company's successful IPO on Nasdaq. In addition, Mr. Kelly also held roles in Elan Corporation and KPMG.
Mr. Kelly holds a Bachelor's degree in Economics from Trinity College, Dublin and is also a member of the Institute of Chartered Accountants in Ireland (ACA).